Cannabinoids are a collection of naturally occurring compounds that are situated in the marijuana plant (cannabis sativa). Cannabidiol (CBD) is the main chemical within the cannabis plant and it is said by the wide scientific community that it has anti inflammatory effects when induced into animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said to have a psychotropic effect. Cannabinoid receptors (CB1 and CB2) are located in the endocannabinoid system and gives cannabinoids power to bind and thrive in the body. This paper will look at how cannabinoids can treat inflammation in the human brain.
Here is the full scientific article if you wish to download it.
Cannabinoid Receptor 1 is a target for therapeutic cannabinoids
The existence of the working cannabinoid CB2 receptors in the central nervous system has sparked a huge controversy in recent times. Before it was considered as an only a back seat receptor, but now it is now regarded functional in a locus in the brain of numerous animal species, including humans. Furthermore, the inducible profile of these receptors under neuroinflammatory situations, in confliction to CB1, makes them elusive target sites for the advancement of novel therapeutic methods. It is said that the unwanted psychotropic impacts mediated by CB1 triggering have a massively limited clinical use of cannabinoid associated chemicals that work on these receptors. This paper has given some recent discoveries on the anti inflammatory qualities of CB2 receptors, as well as new prospects that have been gained based on research of human postmortem brain samples. More so, numerous functioning hypotheses are also proposed and talked about.
Cannabinoids may have anti inflammatory potential
CB2 receptors have been discovered to exist in the central nervous of numerous animal species, thus giving new opportunities for the pharmacological use of cannabinoid drugs. More so, the concept that their expression gets bigger by inflammatory stimuli indicates that they may be in cahoots with the pathogenesis and in the endogenous reaction to injury. Data gotten from animal models display that CB2 receptors may be part of the standard neuroprotective response of the endocannabinoid system by reducing glial reactivity. Neuropathological discoveries in human brains indicate that the upregulation of CB2 receptors is a normal pattern of reaction versus a range of chronic injury of the human central nervous system. In any case, future studies are required to corroborate the possible application of cannabinoid based treatments devoid of unwarranted psychoactive adverse events.